<div id="readability-page-1"><p>LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Savara today and set a price target of $9.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics. According to TipRanks, Brisebois has an average return of <span>2.4%</span> and a 40.11% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara with a $11.00 average price target.</p></div>

SVRA

SBIO

LABU

<p>LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Savara (SVRA) with a price target of $9.00. The overall analyst consensus for Savara is a Strong Buy, with an average price target of $11.00. Brisebois has a 40.11% success rate on his stock recommendations.</p>

Tip Ranks

Savara

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Praxis Precision Medicines

Opus Genetics

LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)